Recombinant IL17A (Secukinumab Biosimilar) anticorps
Cet anticorps Humanized Monoclonal détecte spécifiquement IL17A (Secukinumab Biosimilar) dans FACS et in vivo. Il présente une réactivité envers Humain.
N° du produit ABIN7795097
Aperçu rapide pour Recombinant IL17A (Secukinumab Biosimilar) anticorps (ABIN7795097)
Antigène
IL17A (Secukinumab Biosimilar)
Type d'anticorp
Recombinant Antibody
Reactivité
Humain
Hôte
Humanized
Clonalité
Monoclonal
Conjugué
Cet anticorp IL17A (Secukinumab Biosimilar) est non-conjugé
Application
Flow Cytometry (FACS), In vivo Studies (in vivo)
Classe de qualité
Research Grade
-
-
Expression System
- Mammalian cells
-
Fonction
- Secukinumab Biosimilar, Human IL17A Monoclonal Antibody
-
Attributs du produit
- What is secukinumab biosimilar research grade? Research grade secukinumab biosimilar uses the same protein sequences as the therapeutic antibody secukinumab. Secukinumab, the humanized anti-IL17A monoclonal antibody, inhibits interleukin 17A, which is a member of the cytokine family, and produced mainly by inflammatory T helper 17 cells. IL17A is upregulated in serum of people with psoriasis and in the synovial fluid of people with psoriatic arthritis, and promotes inflammation when it binds to the interleukin-17 receptor which is expressed in various types of cells, including keratinocytes in skin.
-
Purification
- Protein A or G affinity column
-
Pureté
- >95 % by reducing SDS-PAGE
-
niveau d'endotoxine
- < 1 EU per 1 mg of the protein by the LAL method
-
Immunogène
- Human IL17A
-
-
-
-
Indications d'application
- Optimal working dilution should be determined by the investigator.
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- > 3 mg/mL
-
Stock
- 4 °C,-20 °C
-
Stockage commentaire
- Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.
-
-
- IL17A (Secukinumab Biosimilar)
-
Autre désignation
- Secukinumab Biosimilar
-
Classe de substances
- Biosimilar
Antigène
-
Vous êtes ici:
